How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,230 results for

Risperidone

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Two cases of life‐threatening arrhythmia induced by risperidone: evaluation of risperidone and 9‐hydroxy‐risperidone concentrations (PubMed)

Two cases of life‐threatening arrhythmia induced by risperidone: evaluation of risperidone and 9‐hydroxy‐risperidone concentrations Case 1: A 20-year-old woman suffering a suspected overdose was transported to the hospital. She presented bradycardia with wide QRS waves and QT prolongation, followed by cardiac arrest. Extracorporeal cardiopulmonary resuscitation was implemented, improving circulation. Risperidone and 9OH-RIS levels were 9.6 ng/mL and 127.6 ng/mL, respectively. Case 2: A 54 (...) -year-old woman was hospitalized for femoral fracture and underwent surgery. Her electrocardiogram showed bradycardia and complete AV block. Risperidone and 9OH-RIS levels were 3.2 ng/mL and 61.4 ng/mL, respectively.In both cases, only serum concentration of 90H-RIS were elevated.Arrhythmia related to risperidone has proven rare but sometimes fatal. Serum concentrations of risperidone and the metabolite 9-hydroxy-risperidone (9OH-RIS) during these events are seldom documented. As 9OH-RIS shows

Full Text available with Trip Pro

2017 Acute medicine & surgery

2. Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. (PubMed)

Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. Up to 75% of people with serious mental illness (SMI) such as schizophrenia and bipolar disorder have co-occurring substance use disorders (dual diagnosis). Dual diagnosis can have an adverse effect on treatment and prognosis of SMI.To evaluate the effects of risperidone compared to treatment with other antipsychotics (first-generation and other second-generation antipsychotics) used (...) in people with serious mental illness and co-occurring substance misuse.On 6 January 2016 and 9 October 2017, we searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (including trial registers).We selected randomised trials of risperidone versus any other antipsychotic in people with SMI and substance abuse (dual diagnosis). We included trials meeting our inclusion criteria and reporting useable data. We excluded trials that either did not meet our inclusion criteria or met our

2018 Cochrane

3. Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). (PubMed)

Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). Aggressive, agitated or violent behaviour due to psychosis constitutes an emergency psychiatric treatment where fast-acting interventions are required. Risperidone is a widely accessible antipsychotic that can be used to manage psychosis-induced aggression or agitation.To examine whether oral risperidone alone is an effective treatment for psychosis-induced aggression or agitation.We searched the Cochrane (...) of risperidone and other drugs, combinations of drugs or placebo for people exhibiting aggression or agitation (or both) thought to be due to psychosis.We independently inspected all citations from searches, identified relevant abstracts, and independently extracted data from all included studies. For binary data we calculated risk ratio (RR) and for continuous data we calculated mean difference (MD), all with 95% confidence intervals (CI) and used a fixed-effect model. We assessed risk of bias

2018 Cochrane

4. Risperidone

Risperidone Top results for risperidone - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for risperidone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

5. Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study (PubMed)

Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study Risperidone is the first new generation antipsychotic drug to become available as a long-acting injection (LAI). The purpose of this study was to evaluate the effects of switching from oral risperidone to risperidone LAI (RLAI) on cognitive function in stable schizophrenia patients compared with the effects of continuing (...) oral risperidone.Sixteen stable patients who had received risperidone monotherapy for at least 3 months were enrolled (the RLAI group). Before and 24 weeks after switching to RLAI, the Japanese-language version of the Brief Assessment of Cognition in Schizophrenia (BACS-J) and the Positive and Negative Syndrome Scale (PANSS) were administered. To exclude the possibility of learning effects on the BACS-J results, 14 patients with stable schizophrenia who continued oral risperidone treatment were

Full Text available with Trip Pro

2018 Frontiers in Psychiatry

6. WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia. (PubMed)

WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia. Risperidone is one of a number of 'atypical antipsychotics' which are currently being marketed for the treatment of those with schizophrenia, largely on the basis of claims of improved tolerability and effectiveness compared to much cheaper conventional antipsychotics. The efficacy of risperidone has already been compared to conventional drugs, but it remains unclear how risperidone compares with other (...) atypical antipsychotic drugs such as clozapine.To determine the effects of risperidone compared with other atypical antipsychotic drugs for schizophrenia.Electronic searches of Biological Abstracts (1980-1999), The Cochrane Library (Issue 1, 2000), The Cochrane Schizophrenia Group's Register (January 1999), EMBASE (1980-1999), MEDLINE (1966-1999), LILACS (1982-1999), PSYNDEX (1977-1999) and PsycLIT (1974-1999) were undertaken. In addition, pharmaceutical databases on the Dialog Corporation Datastar

Full Text available with Trip Pro

2016 Cochrane

7. Risperidone (depot) for schizophrenia. (PubMed)

Risperidone (depot) for schizophrenia. Risperidone is the first new generation antipsychotic drug made available in a long-acting injection formulation.To examine the effects of depot risperidone for treatment of schizophrenia or related psychoses in comparison with placebo, no treatment or other antipsychotic medication.To critically appraise and summarise current evidence on the resource use, cost and cost-effectiveness of risperidone (depot) for schizophrenia.We searched the Cochrane (...) Schizophrenia Group's Register (December 2002, 2012, and October 28, 2015). We also checked the references of all included studies, and contacted industry and authors of included studies.Randomised clinical trials comparing depot risperidone with other treatments for people with schizophrenia and/or schizophrenia-like psychoses.Two review authors independently selected trials, assessed trial quality and extracted data. For dichotomous data, we calculated the risk ratio (RR), with 95% confidence interval (CI

Full Text available with Trip Pro

2016 Cochrane

8. Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration (...) or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant The safety and scientific validity of this study is the responsibility of the study sponsor and investigators

2016 Clinical Trials

9. The maintenance of modified electroconvulsive therapy combined with risperidone is better than risperidone alone in preventing relapse of schizophrenia and improving cognitive function. (PubMed)

The maintenance of modified electroconvulsive therapy combined with risperidone is better than risperidone alone in preventing relapse of schizophrenia and improving cognitive function. To evaluate the effect of maintenance modified electroconvulsive therapy (MECT) on schizophrenic patients.From June 2012 to June 2014, 62 patients with schizophrenia, who had recovered from a successful course of acute MECT, were recruited. Thirty-one patients received maintenance MECT and risperidone (...) , as the experimental group. Another 31 patients were enrolled in the control group, and received risperidone only. The effects on cognitive functions, clinical symptoms and relapse rate were determined.Patients in the experimental group had a lower relapse rate and longer relapse-free survival time than the controls. Relative to the baseline evaluation, patients showed statistically significant improvement in verbal memory and visual memory. At the final assessment, the scores of verbal and visual memory were

Full Text available with Trip Pro

2017 Arquivos de neuro-psiquiatria

10. Pharmacological interventions: Long-acting injectable risperidone as an option in first-episode psychosis

Pharmacological interventions: Long-acting injectable risperidone as an option in first-episode psychosis Long-acting injectable risperidone as an option in first-episode psychosis | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Long-acting injectable risperidone as an option in first-episode psychosis Article Text Electronic pages Pharmacological interventions Long-acting injectable risperidone as an option in first-episode psychosis Nancy H

2016 Evidence-Based Mental Health

11. Risperidone versus placebo for people with schizophrenia: low quality evidence, unclear benefits

Risperidone versus placebo for people with schizophrenia: low quality evidence, unclear benefits Risperidone versus placebo for people with schizophrenia Search National Elf Service Search National Elf Service » » » » Risperidone versus placebo for people with schizophrenia Jan 13 2017 Posted by Risperidone was one of the first “atypical” antipsychotics to appear in the early 1990s. As a serotonin/dopamine receptor antagonist, it binds to D2 and D3 receptors with 50 and 20 times greater (...) affinity than clozapine and is only 2-3 times less potent than haloperidol (Leyson et al, 1994). In 2007, risperidone became off license and has emerged as the new standard care comparator for schizophrenia. Much of the current evidence for the use of risperidone is based on comparisons to older drugs with poor side effect profiles, such as haloperidol (Hunter et al, 2003). However, comparing risperidone to other antipsychotics underestimates the importance of the placebo effect. With placebo effects

2017 The Mental Elf

12. Risperidone versus placebo for people with schizophrenia

Risperidone versus placebo for people with schizophrenia Risperidone versus placebo for people with schizophrenia Search National Elf Service Search National Elf Service » » » » Risperidone versus placebo for people with schizophrenia Jan 13 2017 Posted by Risperidone was one of the first “atypical” antipsychotics to appear in the early 1990s. As a serotonin/dopamine receptor antagonist, it binds to D2 and D3 receptors with 50 and 20 times greater affinity than clozapine and is only 2-3 times (...) less potent than haloperidol (Leyson et al, 1994). In 2007, risperidone became off license and has emerged as the new standard care comparator for schizophrenia. Much of the current evidence for the use of risperidone is based on comparisons to older drugs with poor side effect profiles, such as haloperidol (Hunter et al, 2003). However, comparing risperidone to other antipsychotics underestimates the importance of the placebo effect. With placebo effects accounting for up to 33% of clinical

2017 The Mental Elf

13. A longitudinal magnetic resonance spectroscopy study investigating effects of risperidone in the anterior cingulate cortex and hippocampus in schizophrenia. (PubMed)

A longitudinal magnetic resonance spectroscopy study investigating effects of risperidone in the anterior cingulate cortex and hippocampus in schizophrenia. Magnetic Resonance Spectroscopy is a popular approach to probe brain chemistry in schizophrenia (SZ), but no consensus exists as to the extent of alterations. This may be attributable to differential effects of populations studied, brain regions examined, or antipsychotic medication effects. Here, we measured neurometabolites (...) in the anterior cingulate cortex (ACC) and hippocampus, two structurally dissimilar brain regions implicated in the SZ pathophysiology. We enrolled 61 SZ with the goal to scan them before and after six weeks of treatment with risperidone. We also scanned 31 matched healthy controls twice, six weeks apart. Using mixed effect repeated measures linear models to examine the effect of group and time on metabolite levels in each voxel, we report an increase in hippocampal glutamate + glutamine (Glx) in SZ compared

2019 Schizophrenia Research

14. Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels. (PubMed)

Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels. We attempted to replicate the efficacy of minocycline, a second-generation tetracycline, as adjunctive therapy for the negative symptoms of schizophrenia, and to investigate its association with pro-inflammatory cytokine levels.Seventy-five schizophrenia patients with negative symptoms entered a 3-month, double blind, randomized, placebo-controlled clinical (...) trial. Subjects were assigned low dose (100 mg per day) or high dose minocycline (200 mg per day) or placebo combined with risperidone. The outcomes used the Scale for the Assessment of Negative Symptoms (SANS) and the Positive and Negative Syndrome Scale (PANSS)-negative subscale. We assessed three pro-inflammatory cytokines in serum: interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α).Subjects receiving high dose minocycline not only had greater improvements

2019 Progress in neuro-psychopharmacology & biological psychiatry

15. In patients receiving palliative care, risperidone or haloperidol increased delirium symptoms vs placebo. (PubMed)

In patients receiving palliative care, risperidone or haloperidol increased delirium symptoms vs placebo. 28320006 2017 12 08 2018 12 02 1539-3704 166 6 2017 03 21 Annals of internal medicine Ann. Intern. Med. In patients receiving palliative care, risperidone or haloperidol increased delirium symptoms vs placebo. JC32 10.7326/ACPJC-2017-166-6-032 Lee Justin J Holbrook Anne A McMaster UniversityHamilton, Ontario, Canada. eng Journal Article Comment United States Ann Intern Med 0372351 0003-4819 (...) 0 Antipsychotic Agents J6292F8L3D Haloperidol L6UH7ZF8HC Risperidone AIM IM JAMA Intern Med. 2017 Jan 1;177(1):34-42 27918778 Antipsychotic Agents Delirium Double-Blind Method Haloperidol Humans Palliative Care Risperidone 2017 3 21 6 0 2017 3 21 6 0 2017 12 9 6 0 ppublish 28320006 2612421 10.7326/ACPJC-2017-166-6-032

2017 Annals of Internal Medicine

16. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. (PubMed)

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Although predominant negative symptoms of schizophrenia can be severe enough to cause persistent impairment, effective treatment options are lacking. We aimed to assess the new generation antipsychotic cariprazine in adult patients with predominant negative symptoms.In this randomised, double-blind, phase 3b trial, we enrolled (...) adults aged 18-65 years with long-term (>2 year), stable schizophrenia and predominant negative symptoms (>6 months) at 66 study centres (mainly hospitals and university clinics, with a small number of private practices) in 11 European countries. Patients were randomly assigned (1:1) by an interactive web response system to 26 weeks of monotherapy with fixed-dose oral cariprazine (3 mg, 4·5 mg [target dose], or 6 mg per day) or risperidone (3 mg, 4 mg [target dose], or 6 mg per day); previous

2017 Lancet

17. Risperidone adjunctive therapy duration in the maintenance treatment of bipolar I disorder: A post hoc analysis. (PubMed)

Risperidone adjunctive therapy duration in the maintenance treatment of bipolar I disorder: A post hoc analysis. Risperidone, an atypical antipsychotic medication, is recommended as a first line treatment for acute mania in patients with bipolar disorder I (BD I). It is unknown if continuing treatment with risperidone adjunct to lithium or valproate after remission of the manic episode offers additional benefit in prevention of mood episode relapse.A post-hoc subgroup analysis was conducted (...) using data from a 52-week, double-blind, placebo controlled trial involving 93 patients treated with oral risperidone adjunct to mood stabilizer, randomized to arms discontinuing risperidone at entry ("0-week arm"), 24 weeks after entry ("24-week arm") or continuing risperidone ("52-week arm"). Time to any episode, manic episode, and depressive episode was compared between arms using Cox regression models.Time to any mood episode was longer in the 24-week arm versus the 0-week arm (HR: 0.57, 95% CI

2019 Journal of Affective Disorders

18. Is risperidone effective in reducing challenging behaviours in individuals with intellectual disabilities after 1 year or longer use? A placebo-controlled, randomised, double-blind discontinuation study. (PubMed)

Is risperidone effective in reducing challenging behaviours in individuals with intellectual disabilities after 1 year or longer use? A placebo-controlled, randomised, double-blind discontinuation study. Many people with intellectual disabilities use risperidone long term for the management of challenging behaviours, despite its limited proof of effectiveness and its clear association with adverse events. Therefore, this study aimed to investigate the effectiveness of ongoing treatment (...) with risperidone in reducing challenging behaviours versus controlled discontinuation on behaviour and health parameters.This was a placebo-controlled, double-blind, randomised discontinuation trial of risperidone. In the discontinuation group, risperidone was gradually replaced by a placebo over 14 weeks, while the control group maintained their existing dosage. Eight weeks after discontinuation, behaviour (as measured by the 'Aberrant Behavior Checklist') and health parameters (dyskinesia, akathisia

2019 Journal of intellectual disability research : JIDR

19. No Differences in Weight Gain Between Risperidone and Aripiprazole in Children and Adolescents After 12 Months. (PubMed)

No Differences in Weight Gain Between Risperidone and Aripiprazole in Children and Adolescents After 12 Months. Weight gain due to the use of second-generation antipsychotics is a major health care issue for adult and paediatric psychiatric patients. Little is known about long-term weight gain effects of aripiprazole compared to risperidone in children and adolescents.The primary aim of this study is to assess whether risperidone and aripiprazole are associated with different weight changes (...) in children and adolescents during the first 12 months of treatment. Secondary aim was to assess the influence of the covariates co-medication, gender and indication on weight change.This study was a retrospective observational cohort study of in- and outpatients of a Dutch mental health organization aged ≤19 years on long-term treatment with risperidone or aripiprazole. Primary outcome measure was body-mass index (BMI) z-score change. Data were extracted from medical charts and analysed using linear

2019 Journal of Child and Adolescent Psychopharmacology

20. CYP2D6 genotype and adverse events to risperidone in children and adolescents. (PubMed)

CYP2D6 genotype and adverse events to risperidone in children and adolescents. There are few and conflicting data on the role of cytochrome P450 2D6 (CYP2D6) polymorphisms in relation to risperidone adverse events (AEs) in children. This study assessed the association between CYP2D6 metabolizer status and risk for risperidone AEs in children.Children ≤18 years with at least 4 weeks of risperidone exposure were identified using BioVU, a de-identified DNA biobank linked to electronic health (...) , and initial dose, poor/intermediate metabolizers had increased AE risk (adjusted odds ratio 2.4, 95% confidence interval 1.1-5.1, P = 0.03).Children with CYP2D6 poor or intermediate metabolizer phenotypes are at greater risk for risperidone AEs. Pre-prescription genotyping could identify this high-risk subset for an alternate therapy, risperidone dose reduction, and/or increased monitoring for AEs.

2019 Pediatric Research

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>